PHAT
Phathom Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Phathom Pharmaceuticals (PHAT) Stock: Buy, Sell, or Hold?
$6.26
-0.02 (-0.32%)
▼
5d:
+23.23%
30d:
-15.41%
90d:
-34.66%
QUANTITATIVE VERDICT
BUY
HIGH Confidence (83%)
Quality Score
65/100
Position
FAIR
30-Day Fair Range
$5.69 – $7.14
Position: FAIR
Forward P/E & Valuation
6.6x
CHEAP
vs 7.4x historical avg
Wall Street Target
$20.05
+219.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$5.04 / $6.38
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
✅ BUY SIGNAL: PHAT trading at deep discount. Market pricing in -3.8% annual earnings decline, creating value opportunity for patient investors.
Get Alerted When PHAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.91
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.15
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAT is currently trading at $6.26, which is considered fair relative to its 30-day fair value range of $5.69 to $7.14. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.6) compared to its historical average (7.4). Remarkably, the market is currently pricing in an annual earnings decline of 3.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAT is in a strong downtrend. The price is approaching resistance at $6.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHAT scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $20.05 (+219.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAT is in a strong downtrend. The price is approaching resistance at $6.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHAT scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $20.05 (+219.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.69 -
$7.14
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
83.3%
Trading Range & Key Levels
30-Day Trading Range
$5.69 -
$7.14
Current vs Trading Range
FAIR
Support Level
$5.04
Resistance Level
$6.38
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (88/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 219.3% below Wall St target ($20.05)
- BULLISH: Bottoming setup score 88/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
6.57
Wall Street Target
$20.05
(+219.3%)
Revenue Growth (YoY)
71.1%
Profit Margin
-30.2%
Valuation Discount vs History
-3.8% cheaper
PE vs Historical
6.6 vs 7.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.8%
(market-implied from PE analysis)
1-Year Target
$6.04
(-4%)
2-Year Target
$5.81
(-8%)
3-Year Target
$5.59
(-11%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
$6.30
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.6 to 7.4
Stabilization Target:
$7.07
(+12.6%)
PE Expansion Potential:
+12.6%
Share PHAT Analysis
Share this live PHAT analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (PHAT)
Bearish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits messages indicate a bullish sentiment towards $PHAT, with one user expressing confidence in the company's business and believing that recent negative actions were orchestrated to sabotage the stock before earnings. No new information was available in the Yahoo Finance news articles.
Key Retail Themes:
Company's strong business position
Perceived attempt to sabotage the stock
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:07 PM ET
Data refreshes hourly during market hours. Next update: 3:07 PM
Data refreshes hourly during market hours. Next update: 3:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 45 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
ABVX
Abivax SA American Depos… |
STRONG BUY
12 analysts |
$164 | 64 BUY |
|
STOK
Stoke Therapeutics Inc |
STRONG BUY
14 analysts |
$46 | 54 HOLD |
|
STRO
Sutro Biopharma |
STRONG BUY
14 analysts |
$47 | 58 HOLD |
Advanced PHAT Option Strategies
Professional options setups generated by AI based on today's PHAT price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PHAT Research Pages
